Kaashoek M J, Moerman A, Madić J, Rijsewijk F A, Quak J, Gielkens A L, van Oirschot J T
Central Veterinary Institute (CDI-DLO), Department of Open Virology, Lelystad, The Netherlands.
Vaccine. 1994 Apr;12(5):439-44. doi: 10.1016/0264-410x(94)90122-8.
We examined the vaccine properties of a conventionally attenuated bovine herpesvirus type 1 (BHV-1) mutant strain A. This strain has a deletion that encompasses the glycoprotein E gene and may therefore be used as a marker vaccine. We compared strain A with a commercial live BHV-1 vaccine B. Calves were intranasally vaccinated with strain A or with vaccine B. Strain A was virtually avirulent for young calves. After challenge, vaccinated calves were protected against disease and virus shedding was considerably reduced. After dexamethasone treatment, strain A was not recovered, whereas vaccine B and challenge virus were. We conclude that strain A is suitable for inclusion in a vaccine and has the potential advantage of being used as a marker vaccine.
我们检测了传统减毒的1型牛疱疹病毒(BHV-1)突变株A的疫苗特性。该毒株存在一个包含糖蛋白E基因的缺失,因此可用作标记疫苗。我们将毒株A与一种市售的BHV-1活疫苗B进行了比较。给犊牛经鼻接种毒株A或疫苗B。毒株A对幼龄犊牛几乎无致病性。攻毒后,接种疫苗的犊牛受到疾病保护,病毒排出量大幅减少。地塞米松处理后,未再分离到毒株A,而疫苗B和攻毒病毒仍可分离到。我们得出结论,毒株A适合用于疫苗,具有用作标记疫苗的潜在优势。